EU Approvals: Rinvoq Cleared For RA
AbbVie's Selective JAK Inhibitor A Driver Of Future Growth
AbbVie’s upadacitinib has become the latest JAK inhibitor to be approved in the EU for active rheumatoid arthritis, and its selectivity could allow it to compete effectively with established therapies including other JAK inhibitors, TNF-inhibiting biologics and biosimilars.
You may also be interested in...
The European Medicines Agency's drug safety committee has concluded that Pfizer's Xeljanz could increase the risk of blood clots in patients who are already at high risk. The committee has also recommended restrictions on the use of Sanofi's multiple sclerosis drug, Lemtrada.
Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.